Do you want to read an article? Please log in or register.
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial
Myeloproliferative Neoplasms (MPNs)
Related content
Myeloproliferative Neoplasms (MPNs)
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
J Clin Oncol
Kuykendall AT, Bankar A, Pettit KM, Shatzel J, Lucchesi A, García-Gutiérrez V, Mayer J, Yacoub A, Gill H, Sasca D, Scandura JM, Kremyanskaya M, Ross DM, Palandri F, Fox ML, Vannucchi AM, Haque T, Koschmieder S, Kiladjian JJ, Oyuela P, Dinh P, Xiao J, Valone FH, Gupta S, Khanna S, Molina A, Pemmaraju N, VERIFY Investigators
doi: 10.1200/JCO-26-00992
Breast Cancer
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial
Ann Oncol
Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)
doi: 10.1016/j.annonc.2026.05.703
Central Nervous System Tumors
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
J Clin Oncol
Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Sargos P, Taphoorn MJB, Vauleon E, Philips C, Kros JM, Bady P, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Jacob J, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Balana C, Azevedo ALS, Clement PM, Berghoff A, Tzuk-Shina T, Weller M, Nordal RA, Rees J, Lacombe DA, Mason WP, Stupp R
doi: 10.1200/JCO-25-02735
Gastrointestinal Cancer
COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer
J Clin Oncol
Azad NS, Hu I, Pathak P, Sahin I, Aranha O, Iyer R, Heestand G, Liao CY, Hochster HS, Kalyan A, El-Khoueiry A, Paulson AS, Kelley RK, Borad M, Goyal L, Sirard CA, Schuetz TJ, Javle M
doi: 10.1200/JCO-26-02188
Lung, Respiratory and Thoracic Cancer
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial
J Thorac Oncol
Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC
doi: 10.1016/j.jtho.2026.103609
Breast Cancer
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial
Int J Cancer
Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, Brucker SY, Köhler U, Heinrich G, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Rack B, Heublein S, Ziegler P
doi: 10.1002/ijc.70528
RECOMMENDED
Breast Cancer
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee
doi: 10.1200/JCO-25-02705
Gastrointestinal Cancer
Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Lancet Oncol
Quik JSE, Vollebergh MA, Retèl VP, van der Sluis K, Koemans WJ, van der Kaaij RT, Voets MM, Luyer MDP, van Hellemond IEG, Wijnhoven BPL, Mostert B, van Hillegersberg R, Mohammad NH, van Etten B, de Groot DJ, Helminen O, Hedberg J, Cashin PH, Harbjerg JL, Veenhof AAFA, Hartemink KJ, Kodach LL, van der Noort V, van Sandick JW, PERISCOPE II consortium
doi: 10.1016/S1470-2045(26)00144-0
Breast Cancer
Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer
CA Cancer J Clin
Kaidar-Person O, Weltens CG, Fortpied C, Scheijmans LJEE, Kirkove CY, Budach V, Peignaux-Casasnovas K, Valli M, Peters M, van der Leij F, Rivera S, Weidner N, van den Bongard DHJG, Linsenmeier C, Abdah-Bortnyak R, Hosni S, Koiter E, Engelen AM, Baten A, Champezou L, Fourquet A, Bartelink HGMM, Struikmans H, Poortmans PMP, European Organization for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups
doi: 10.3322/caac.70082